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Osteoprotegerin (OPG) is a glycoprotein involved in bone metabolisms and with a regulatory role in immune,
skeletal and vascular systems. Recently, circulating OPG levels have emerged as independent biomarkers of
cardiovascular disease (CVD) in patients with acute or chronic heart disease, as well as in the healthy population.
Furthermore, OPG has been implicated in various inflammations and linked to diabetes and poor glycaemic control.
This review focuses on the relations between circulating OPG levels and cardiovascular complications, with special
emphasis on diabetic patients. OPG levels were observed to increase concurrently with the severity of diabetic
complications, that is, with the highest circulating OPG levels observed in diabetic patients dying from CVD.
Although the clinical prognostic use of OPG may seem far away, OPG does look promising as a biomarker in order
to help the cardiologist to a better risk-stratification of the patients.
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In 1997 (Simonet et al. 1997) characterized osteopro-
tegerin (OPG) (also known as Osteoclastogenesis In-
hibitory Factor (OCIF) (Yamaguchi et al. 1998) or
tumour necrosis factor receptor superfamily member
11b (TNFRSF11B)) as a secreted glycoprotein that
regulates bone resorption. OPG is synthesized as a mo-
nomer (60 kDa) and assembled as a homodimer within
the cell, and then secreted mainly as a disulphide-
linked homodimer into the circulation (Yamaguchi
et al. 1998; Simonet et al. 1997). OPG was identified as
a cytokine and member of the TNF receptor superfa-
mily, and binds to two ligands, RANKL (receptor ac-
tivator of nuclear factor kB ligand), a critical cytokine
for osteoclast differentiation, and TRAIL (TNF-related
apoptosis-inducing ligand), involved in immune surveil-
lance (Emery et al. 1998; Schoppet et al. 2002). Thus,
acting as a decoy receptor for RANKL and TRAIL,
OPG inhibits the nuclear factor-kB’s regulatory effects
on inflammation, skeletal, and vascular systems and
prevents TRAIL-induced apoptosis.Correspondence: mette.bjerre@ki.au.dk
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in any medium, provided the original work is pThe OPG molecule consists of three structural domains
influencing the biological function. The N-terminal part is
a cysteine-rich domain important for dimerization and
osteoclastgenesis whereas the C-terminal contains a death
domain and a domain for heparin binding (Yamaguchi
et al. 1998). The latter is capable of interacting with differ-
ent proteoglycans including heparan sulphate and heparin
(Theoleyre et al. 2006). Binding between OPG and hepa-
ran sulphate present at the cell surface has been reported
in myeloma cells (Standal et al. 2002) and human mono-
cytes (Mosheimer et al. 2005). OPG is highly expressed in
heart, lung, kidney, liver and bone marrow among other
tissues (Simonet et al. 1997) and produced by vascular
endothelial and smooth muscle cells (SMC) and secreted
into the circulation (Hofbauer et al. 2001). OPG is found
in the Weibel Palade bodies and in platelets where it is as-
sociated with von Willebrandt factor (Zannettino et al.
2005; Chollet et al. 2010). TNF-α and IL-1β were found to
increase the OPG levels, indicating that activation of
endothelial cells by pro-inflammatory cytokines might be
a possible source of circulating OPG in patients with car-
diovascular disease (CVD) (Hofbauer and Schoppet 2004;
Schoppet et al. 2002). In vitro experiments show that hu-
man SMCs produce large OPG amounts (up to 30 times
more than endothelial cells) after stimulation with TNF-α,
whereas insulin was found to decrease the productionn Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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mRNA indicating a transcriptional regulation.
OPG and CVD
Lately, a connection between bone regulatory proteins
and vascular biology has attracted attention, suggesting
OPG as a possible mediator of vascular calcification
(Flyvbjerg 2010; Reid and Holen 2009). Arterial calcifi-
cation is part of the atherosclerotic process leading to
clinical CVD. OPG is reported to be present in athero-
sclerotic plaques and studies have shown that OPG co-
localise with the area of calcification (Dhore et al. 2001;
Schoppet et al. 2004). Several prognostic associations in-
volving circulating OPG levels have been reported, both
regarding risk of CVD and of the subsequent risk of
death (Montagnana et al. 2013). The link between OPG
and CVD was further supported by observations of OPG
promoter polymorphism that is related to vascular
morphology and function (Brandstrom et al. 2002; Soufi
et al. 2004). The clinical relevance of the polymorphisms
is based on the fact that plasma OPG levels and func-
tional activity may be influenced. Recently, three poly-
morphisms (T245G, T950C and G1181C) in the OPG
gene, which are reported to be associated with increased
serum OPG levels, were found more frequently in
patients with carotid plaques (Straface et al. 2011) or
in diabetic patients with a history of ischemic stroke
(Biscetti et al. 2013).
Using animal models, Bucay et al. showed that OPG
knockout mice developed spontaneous arterial calcifica-
tion, thus OPG appears to be protective against vascular
calcification (Bucay et al. 1998). Furthermore, in ApoE
knockout mice, a well-known model for atherosclerosis,
depletion of OPG increased atherosclerotic lesion progres-
sion and calcification (Bennett et al. 2006). Therefore, the
elevated OPG levels may prevent cardiovascular events in
humans. However, the protective role of OPG found in
animal models has not been observed in humans. In fact,
increased OPG levels have consistently been associated
with the severity of CVD.
The first connection between OPG and CVD in
humans was published in 2001 by Browner et al. report-
ing an association between high OPG levels in plasma
and increased CV mortality in a cohort of 490 women
above the age of 65 (Browner et al. 2001). Several as-
sociations between OPG levels and traditional CV risk
factors have now been reported, including positive cor-
relations with smoking, fasting glucose levels, older age,
diabetes, and renal impairment (Kiechl et al. 2006). In
addition, OPG concentrations are positively correlated
with coronary calcification, vascular stiffness and the
presence of unstable atherosclerotic plaques (Nybo and
Rasmussen 2008a; Montecucco et al. 2007). We have
recently shown that increased serum OPG levels onadmission for acute myocardial infarct (AMI) are associ-
ated with decreased microcirculation after revasculariza-
tion (Logstrup et al. 2013). In population-based cohort
studies, increased OPG levels were found to be associ-
ated with the future risk of myocardial infarct, ischemic
stroke, and CV mortality (Kiechl et al. 2004; Vik et al.
2011; Mogelvang et al. 2013; Abedin et al. 2007). In an
investigation of a large number of patients with different
types of CVD, we found associations between increasing
OPG levels and the severity of CVD (Figure 1).
Increased OPG levels have recently been associated
with a greater extent of myocardial damage and lower
myocardial salvage, estimated by magnetic resonance
imaging or by single photon emission computed tomo-
graphy (SPECT), in STEMI patients treated with pPCI
(Fuernau et al. 2012; Andersen et al. 2011). However,
we could not confirm this in our very similar set-up
(patients (N = 219), pPCI and SPECT imaging). Instead,
our results suggest that increased circulating OPG levels
are not directly involved in the myocardial damage after
STEMI (Bjerre et al. manuscript submitted). Interest-
ingly, we showed that high OPG levels still predicted a
significantly increased risk of major CV events. The fact
that OPG is present in platelets may be the link between
increased OPG levels and thrombosis. Thus, the OPG
levels may simply reflect extensive CVD.
OPG, Diabetes and CVD
The initial lesion of atherosclerosis involves changes in
the vascular endothelium and patients with diabetes
show endothelial dysfunction as well as associated CV
risk factors such as hypertension, obesity and dyslipidae-
mia (Versari et al. 2009). Thus, diabetes plays a critical
role in the development of CVD. In fact, the mortality
from AMI is increased five-fold in diabetic patients
(Hansen et al. 2007). Interestingly, Redgrave et al. repor-
ted no fundamental difference between carotid plaques
from diabetics and non-diabetics, but surface thrombus
seems to persist longer after ischemic symptoms in pla-
ques from diabetics or patients with impaired glucose
tolerance (Redgrave et al. 2008). Hyperglycaemia acceler-
ates atherosclerosis and increases the risk for AMI, thus
worsening the prognosis in diabetics (Mazzone et al.
2008; Schramm et al. 2008). Changes in the vascular
endothelium in diabetics may account for the association
with multiple vascular complications. The UKPDS study
reported a positive effect on the vascular system by low-
ering the blood glucose (Holman et al. 2008). Note-
worthy, a positive correlation between fructosamine and
serum OPG was found in a group of elderly women with
diabetes, but not in the non-diabetic controls (Browner
et al. 2001). In agreement with this, a significant corre-
lation between HbA1c and OPG was shown in patients
with type 1 diabetes (T1D) or type 2 diabetes (T2D)
Figure 1 Increasing OPG levels associate with the severity of the cardiovascular disease. All analyses are performed in The Medical
Research Laboratory (OPG levels median (IQR)) ((Mogelvang et al. 2012; Roysland et al. 2010; Roysland et al. 2012; Pedersen et al. 2012) and Bjerre
et al. unpublished data).
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children with T1D had higher OPG levels than healthy
age, sex and BMI matched children (Galluzzi et al. 2005),
and OPG was significantly correlated with HbA1c. These
findings were later confirmed in rodent models of expe-
rimental diabetic arteriopathy (Heinonen et al. 2007;
Vaccarezza et al. 2007).
Browner et al. reported 30% higher serum OPG levels
in women with diabetes as compared to healthy individ-
uals (Browner et al. 2001), and OPG has been found to
accumulate in aortic tissue from patients with T1D and
T2D (Olesen et al. 2005). We have shown that serum
OPG is associated with the development and progressionFigure 2 OPG levels increase with the severity of complications in dia
Research Laboratory (Mogelvang et al. 2012; Chen et al. 2011; Gordin et al.of diabetic complications in a large group of adults with
T1D (N = 1939), and that OPG is an independent pre-
dictor of CV complications (Gordin et al. 2013). In ad-
dition, patients with renal impairment had elevated OPG
levels compared to T1D patients without overt kidney dis-
ease. These results correlated with the findings by Jorsal
et al., showing that increased OPG levels predicted the se-
verity of diabetic nephropathy, and that OPG is an inde-
pendent marker of mortality (Jorsal et al. 2008).
Similarly, Knudsen et al. reported increased OPG levels
in T2D patients with microvascular complications com-
pared to T2D patients without complications (Knudsen
et al. 2003). Anard and co-workers reported that elevatedbetic patients. All OPG analyses are performed in The Medical
2013) and Bjerre et al. unpublished data).
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complicated T2D (Anand et al. 2006) and we showed
increased OPG levels in patients with uncomplicated
well-controlled T2D (Chen et al. 2011). In a prospective
observational study with a 17-year-follow-up period, in-
creased OPG levels were reported as a strong predictor of
all-cause mortality in T2D patients, independent of tra-
ditional cardiovascular risk-factors (Reinhard et al. 2010).
A few studies contradicted the numerous studies de-
scribed above. Identical OPG levels was observed in
obese and lean individuals and in T2D patients (N = 10
in each group). However, acute hyperinsulinemia de-
creased OPG with diminished effect in obese individuals
and T2D patients (Jorgensen et al. 2009). In addition,
significantly low OPG levels were reported in T1D pa-
tients with normoalbuminuria compared with healthy
controls (Singh et al. 2010). In a group of diabetic pa-
tients with stable coronary artery disease (CAD) we
found significantly increased serum OPG levels as com-
pared to the non-diabetic CAD patients (Bjerre et al.
submitted for publication). Of notice, significantly in-
creased OPG levels were found in the diabetic patients
who died compared with surviving diabetic patients.
Collectively, increasing OPG concentrations in diabetic
patients seem to follow the severity of complications
(Figure 2).
OPG as a Biomarker
Taken together, these studies suggest that OPG may be a
new promising marker for risk prediction in CVD. How-
ever, before implementation of OPG as a biomarker
some considerations must be taken into account.
OPG can be detected in both serum and plasma, but
the levels are not completely comparable, and EDTA
plasma seems to be recommended (Chan et al. 2003).
The OPG molecule primarily circulates as a homodimer,
but also monomer or complexes with RANKL or TRAIL
may be present, which may interfere with the measure-
ments. Furthermore, the circulating OPG reflects the
production from several tissues, which makes it difficult
to specify the site of origin.
Of notice, the OPG molecule contains a heparin bin-
ding domain and in vitro studies have shown a rapid
OPG release from smooth muscle cells (SMC) after hep-
arin treatment (Nybo and Rasmussen 2008b). According
to guidelines, all patients with CV complications are
treated with unfractionated heparin within the ambu-
lance. In vivo studies with intravenous heparin infusions
in healthy individuals showed a 2.2 fold increase in the
circulating OPG levels within 5 min as compared to pre-
injection values, but the OPG levels were significantly
decreased or normalized within 1 hour (Vik et al. 2007;
Nybo and Rasmussen 2008b). The time for collection of
blood samples is therefore of great importance and canmake it difficult to compare studies of OPG levels in pa-
tients with acute CV events.
In addition, OPG levels are gender-specific, i.e. women
have higher OPG levels than men. Furthermore, OPG is
strongly associated with age (Mogelvang et al. 2013;
Omland et al. 2007), which also needs to be considered
before appointing threshold or risk stratification.
Conclusion
At first glance, it may seem contradictory that OPG – a
putative beneficial calcification inhibitor – accumulates
in the arterial system in diabetes and that high levels of
OPG are risk markers for cardiovascular death. However,
the accumulation may be a consequence of a compen-
satory vascular response towards calcification and thus
associated with endothelial dysfunction. Since the in-
flammatory response is a natural sequence of a plaque
rupture, OPG may be up regulated to prevent further
damage, rather than being responsible for the initial
damage.
Despite the growing evidence, the precise mechanism
by which OPG, diabetes and cardiovascular disease are
connected has not yet been found and the actual role of
OPG in atherosclerotic calcification remains speculative.
Although the prognostic use of OPG in the clinic seems
far away, it does look promising in order to help the car-
diologist to a better risk-stratification of the patients.
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